Juan J Badimon

List of Publications by Year
in descending order

198	24,592	14614 66	6979 154
papers	citations	h-index	g-index

206	206	206	16626
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes. New England Journal of Medicine, 1992, 326, 242-250.	13.9	3,135
2	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1664-1672.	1.6	2,308
3	The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes. New England Journal of Medicine, 1992, 326, 310-318.	13.9	1,673
4	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1772-1778.	1.6	1,562
5	Atherothrombosis and High-Risk Plaque. Journal of the American College of Cardiology, 2005, 46, 937-954.	1.2	666
6	Plaque Neovascularization Is Increased in Ruptured Atherosclerotic Lesions of Human Aorta. Circulation, 2004, 110, 2032-2038.	1.6	607
7	From Vulnerable Plaque to Vulnerable Patientâ€"Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report. American Journal of Cardiology, 2006, 98, 2-15.	0.7	594
8	Noninvasive In Vivo Human Coronary Artery Lumen and Wall Imaging Using Black-Blood Magnetic Resonance Imaging. Circulation, 2000, 102, 506-510.	1.6	561
9	Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. Journal of the American College of Cardiology, 1994, 23, 1562-1569.	1.2	551
10	Effects of Lipid-Lowering by Simvastatin on Human Atherosclerotic Lesions. Circulation, 2001, 104, 249-252.	1.6	476
11	Tissue Factor Modulates the Thrombogenicity of Human Atherosclerotic Plaques. Circulation, 1997, 95, 594-599.	1.6	475
12	Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions. Circulation, 2002, 106, 2884-2887.	1.6	467
13	Empagliflozin Ameliorates Adverse LeftÂVentricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Journal of the American College of Cardiology, 2019, 73, 1931-1944.	1.2	411
14	Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood, 2000, 96, 170-175.	0.6	385
15	In Vivo Magnetic Resonance Evaluation of Atherosclerotic Plaques in the Human Thoracic Aorta. Circulation, 2000, 101, 2503-2509.	1.6	316
16	The Diagnostic Accuracy of Ex Vivo MRI for Human Atherosclerotic Plaque Characterization. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2756-2761.	1.1	302
17	Randomized Trial of Empagliflozin in Nondiabetic Patients With HeartÂFailure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 243-255.	1.2	280
18	Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity. Circulation, 2003, 107, 973-977.	1.6	277

#	Article	IF	Citations
19	Diesel exhaust inhalation increases thrombus formation in man. European Heart Journal, 2008, 29, 3043-3051.	1.0	271
20	Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Simvastatin on Human Atherosclerotic Lesions. Journal of the American College of Cardiology, 2005, 46, 106-112.	1.2	257
21	Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences. Annals of Internal Medicine, 2001, 134, 224.	2.0	253
22	Local Inhibition of Tissue Factor Reduces the Thrombogenicity of Disrupted Human Atherosclerotic Plaques. Circulation, 1999, 99, 1780-1787.	1.6	250
23	Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences*1. European Heart Journal, 2004, 25, 1197-1207.	1.0	240
24	Noninvasive In Vivo High-Resolution Magnetic Resonance Imaging of Atherosclerotic Lesions in Genetically Engineered Mice. Circulation, 1998, 98, 1541-1547.	1.6	224
25	Pathophysiology of Acute Coronary Syndrome. Current Atherosclerosis Reports, 2014, 16, 401.	2.0	217
26	Acute coronary syndromes: biology. Lancet, The, 1999, 353, s5-s9.	6.3	215
27	Mouse Model of Femoral Artery Denudation Injury Associated With the Rapid Accumulation of Adhesion Molecules on the Luminal Surface and Recruitment of Neutrophils. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 335-342.	1.1	201
28	Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. Journal of the American College of Cardiology, 1999, 33, 1294-1304.	1.2	184
29	Progression and Regression of Atherosclerotic Lesions. Circulation, 2002, 105, 993-998.	1.6	180
30	Particle Traps Prevent Adverse Vascular and Prothrombotic Effects of Diesel Engine Exhaust Inhalation in Men. Circulation, 2011, 123, 1721-1728.	1.6	178
31	Atherothrombosis and High-Risk Plaque. Journal of the American College of Cardiology, 2005, 46, 1209-1218.	1.2	157
32	Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion. Circulation, 2016, 133, 954-966.	1.6	155
33	Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. Journal of the American College of Cardiology, 2001, 38, 1307-1312.	1.2	150
34	Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thrombosis and Haemostasis, 2003, 90, 377-384.	1.8	150
35	Chronic Thrombus Detection With In Vivo Magnetic Resonance Imaging and a Fibrin-Targeted Contrast Agent. Circulation, 2005, 112, 1594-1600.	1.6	150
36	Pathogenetic concepts of acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, S7-S14.	1.2	143

#	Article	IF	Citations
37	Early Metoprolol Administration Before Coronary Reperfusion Results in Increased Myocardial Salvage. Circulation, 2007, 115, 2909-2916.	1.6	142
38	MRI and Characterization of Atherosclerotic Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1065-1074.	1.1	138
39	Serial In Vivo MRI Documents Arterial Remodeling in Experimental Atherosclerosis. Circulation, 2000, 101, 586-589.	1.6	137
40	Does shear stress modulate both plaque progression and regression in the thoracic aorta?. Journal of the American College of Cardiology, 2005, 45, 846-854.	1.2	127
41	Evolving Concepts in the Triad of Atherosclerosis, Inflammation and Thrombosis. Journal of Thrombosis and Thrombolysis, 2004, 17, 35-44.	1.0	123
42	Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thrombosis and Haemostasis, 2007, 98, 883-888.	1.8	123
43	Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration. Journal of the American College of Cardiology, 2008, 51, 1104-1109.	1.2	122
44	Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF. JACC: Heart Failure, 2021, 9, 578-589.	1.9	118
45	In vivo noninvasive detection and age definition of arterial thrombus by MRI. Journal of the American College of Cardiology, 2002, 39, 1366-1373.	1.2	115
46	Caspase-3 and Tissue Factor Expression in Lipid-Rich Plaque Macrophages. Circulation, 2004, 109, 2001-2008.	1.6	115
47	Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic HeartÂFailure. JACC: Cardiovascular Imaging, 2021, 14, 393-407.	2.3	114
48	Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice. Circulation, 2001, 103, 2604-2609.	1.6	112
49	Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nuclear Medicine, 2006, 6, 3.	1.4	112
50	Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2021, 77, 1660-1669.	1.2	111
51	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. American Heart Journal, 2016, 182, 125-134.	1.2	108
52	Systems Pharmacology of Adverse Event Mitigation by Drug Combinations. Science Translational Medicine, 2013, 5, 206ra140.	5.8	105
53	Noninvasive In Vivo Magnetic Resonance Imaging of Experimental Coronary Artery Lesions in a Porcine Model. Circulation, 2000, 101, 2956-2961.	1.6	102
54	Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. Journal of the American College of Cardiology, 2001, 37, 1149-1154.	1.2	102

#	Article	IF	Citations
55	The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis. Journal of the American College of Cardiology, 2004, 43, 464-473.	1.2	99
56	High resolution ex vivo magnetic resonance imaging of in situ coronary and aortic atherosclerotic plaque in a porcine model. Atherosclerosis, 2000, 150, 321-329.	0.4	95
57	Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type. Atherosclerosis, 2012, 220, 72-77.	0.4	95
58	Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and compositionâ€"a magnetic resonance imaging study. European Heart Journal, 2005, 26, 1557-1561.	1.0	91
59	Beginning to Understand High-Density Lipoproteins. Endocrinology and Metabolism Clinics of North America, 2014, 43, 913-947.	1.2	85
60	Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thrombosis and Haemostasis, 2008, 100, 76-82.	1.8	84
61	The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMPâ€1 and MMPâ€9 in human macrophages in vitro. FASEB Journal, 2011, 25, 35-44.	0.2	81
62	Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2316-2321.	1.1	79
63	Clinical implications of clopidogrel resistance. Thrombosis and Haemostasis, 2008, 100, 196-203.	1.8	79
64	The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1287-1302.	1.5	78
65	Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. Journal of the American College of Cardiology, 2000, 36, 2303-2310.	1.2	74
66	Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. European Heart Journal, 2010, 31, 1573-1582.	1.0	74
67	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. Journal of the American College of Cardiology, 2020, 75, 578-586.	1.2	66
68	In Vivo 16-Slice, Multidetector-Row Computed Tomography for the Assessment of Experimental Atherosclerosis. Circulation, 2004, 110, 1467-1472.	1.6	64
69	Effect of p27 Deficiency and Rapamycin on Intimal Hyperplasia: In Vivo and In Vitro Studies Using a p27 Knockout Mouse Model. Laboratory Investigation, 2001, 81, 895-903.	1.7	61
70	New Understanding of Atherosclerosis (Clinically and Experimentally) with Evolving MRI Technology in Vivo. Annals of the New York Academy of Sciences, 2001, 947, 181-198.	1.8	61
71	Comparison of Platelet Function and Morphology in Patients Undergoing Percutaneous Coronary Intervention Receiving Bivalirudin Versus Unfractionated Heparin Versus Clopidogrel Pretreatment and Bivalirudin. American Journal of Cardiology, 2007, 100, 417-424.	0.7	58
72	Cardiovascular implications of HIV-induced dyslipidemia. Atherosclerosis, 2011, 219, 384-389.	0.4	58

#	Article	IF	Citations
73	Macrophages Transmit Potent Proangiogenic Effects of oxLDL In Vitro and In Vivo Involving HIF-1Î± Activation: a Novel Aspect of Angiogenesis in Atherosclerosis. Journal of Cardiovascular Translational Research, 2013, 6, 558-569.	1.1	57
74	Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. European Heart Journal, 2010, 31, 2049-2057.	1.0	56
75	Genesis and Dynamics of Atherosclerotic Lesions: Implications for Early Detection. Cerebrovascular Diseases, 2009, 27, 38-47.	0.8	55
76	The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion. International Journal of Cardiology, 2011, 147, 428-432.	0.8	55
77	Diagnosis of Atherosclerosis by Imaging. American Journal of Medicine, 2009, 122, S15-S25.	0.6	54
78	Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 275-285.	1.5	53
79	Thrombi of Different Pathologies: Implications for Diagnosis and Treatment. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 274-291.	0.4	51
80	Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the â€œCardiac Benefitsâ€•of Empagliflozin Independent of its Hypoglycemic Activity?. Cardiovascular Drugs and Therapy, 2019, 33, 87-95.	1.3	51
81	A Novel Nonobstructive Intravascular MRI Coil. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 346-350.	1.1	50
82	Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. American Journal of Cardiology, 2000, 86, 246-249.	0.7	49
83	Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: In vivo demonstration by high-resolution MRI. Atherosclerosis, 2007, 190, 106-113.	0.4	48
84	Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening. Atherosclerosis, 1998, 140, 307-314.	0.4	47
85	The development of endotension is associated with increased transmission of pressure and serous components in porous expanded polytetrafluoroethylene stent-grafts: Characterization using a canine model. Journal of Vascular Surgery, 2006, 43, 109-116.	0.6	46
86	Upâ€regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoAâ€I‹sub›Milano‹/sub›. Journal of Cellular and Molecular Medicine, 2009, 13, 3226-3235.	1.6	46
87	Experimental Models for the Investigation of High-Density Lipoproteinâ€“Mediated Cholesterol Efflux. Current Atherosclerosis Reports, 2011, 13, 266-276.	2.0	45
88	Contrast-Enhanced Ultrasound Imaging Detects Intraplaque Neovascularization in an Experimental Model of Atherosclerosis. JACC: Cardiovascular Imaging, 2010, 3, 1256-1264.	2.3	44
89	Alternatively Spliced Tissue Factor Promotes Plaque Angiogenesis Through the Activation of Hypoxia-Inducible Factor-1Î± and Vascular Endothelial Growth Factor Signaling. Circulation, 2014, 130, 1274-1286.	1.6	44
90	HDL-cholesterol: Is it really good?. Biochemical Pharmacology, 2008, 76, 443-452.	2.0	41

#	Article	IF	Citations
91	In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. International Journal of Cardiovascular Imaging, 2009, 25, 251-257.	0.7	40
92	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. Cardiovascular Drugs and Therapy, 2018, 32, 213-222.	1.3	40
93	The Sum of Two Evils. Journal of the American College of Cardiology, 2014, 64, 1926-1928.	1.2	39
94	Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance. International Journal of Molecular Sciences, 2019, 20, 3289.	1.8	37
95	Antithrombotic effects of Abciximab. American Journal of Cardiology, 2000, 85, 1167-1172.	0.7	36
96	Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. European Heart Journal, 2012, 33, 264-273.	1.0	36
97	Reperfusion-triggered stress protein response in the myocardium is blocked by post-conditioning. Systems biology pathway analysis highlights the key role of the canonical aryl-hydrocarbon receptor pathway. European Heart Journal, 2013, 34, 2082-2093.	1.0	36
98	Antithrombotic Effects of DX-9065a, a Direct Factor Xa Inhibitor. Thrombosis and Haemostasis, 2002, 88, 733-738.	1.8	35
99	Prostanoid and TP-receptors in atherothrombosis: Is there a role for their antagonism?. Thrombosis and Haemostasis, 2010, 104, 949-954.	1.8	35
100	Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thrombosis and Haemostasis, 2013, 110, 118-123.	1.8	35
101	Intimal Tissue Factor Activity Is Released from the Arterial Wall after Injury. Thrombosis and Haemostasis, 2000, 83, 622-628.	1.8	32
102	Diagnosis of Isolated Noncompaction of the Myocardium by Magnetic Resonance Imaging. Circulation, 2002, 105, .	1.6	32
103	Lethal myocardial reperfusion injury: A necessary evil?. International Journal of Cardiology, 2011, 151, 3-11.	0.8	30
104	Tissue Factor Coagulation Pathway: A New Therapeutic Target in Atherothrombosis. Journal of Cardiovascular Pharmacology, 2004, 43, 669-676.	0.8	29
105	Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102417.	1.8	29
106	Thrombin/inflammation paradigms: A closer look at arterial and venous thrombosis. American Heart Journal, 2005, 149, S19-S31.	1.2	27
107	Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgeryâ˜†â˜†â˜†. Interactive Cardiovascular and Thoracic Surgery, 2010, 10, 863-867.	0.5	27
108	Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	26

#	Article	IF	Citations
109	A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel in a randomised phase I study. Thrombosis and Haemostasis, 2010, 103, 205-212.	1.8	25
110	Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. International Journal of Cardiology, 2011, 153, 256-261.	0.8	24
111	Atherothrombosis: the role of tissue factor. International Journal of Biochemistry and Cell Biology, 2004, 36, 25-30.	1.2	23
112	Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. Current Opinion in Cardiology, 2003, 18, 286-294.	0.8	22
113	Reduced Acute Vascular Injury and Atherosclerosis in Hyperlipidemic Mice Transgenic for Lysozyme. American Journal of Pathology, 2006, 169, 303-313.	1.9	22
114	Badimon Perfusion Chamber: An Ex Vivo Model of Thrombosis. Methods in Molecular Biology, 2018, 1816, 161-171.	0.4	22
115	Overview of Aspirin and Platelet Biology. American Journal of Cardiology, 2021, 144, S2-S9.	0.7	22
116	Quantification and immunolocalization of apolipoprotein E in experimental atherosclerosis. Atherosclerosis, 1986, 61, 57-66.	0.4	21
117	The Mikamo Lecture 2002. Therapeutic Targets for the Treatment of Atherothrombosis in the New Millennium-Clinical Frontiers in Atherosclerosis Research.. Circulation Journal, 2002, 66, 783-790.	0.7	21
118	Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?. Internal and Emergency Medicine, 2011, 6, 29-34.	1.0	21
119	Targeting thrombogenicity and inflammation in chronic HIV infection. Science Advances, 2019, 5, eaav5463.	4.7	21
120	Pharmacology of thienopyridines: rationale for dual pathway inhibition. Country Review Ukraine, 2006, 8, G3-G9.	0.8	20
121	Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis, 2008, 201, 76-84.	0.4	20
122	Development of a preclinical model of ischemic cardiomyopathy in swine. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H530-H537.	1.5	20
123	Value or desirability of hemorheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials. Current Opinion in Lipidology, 2001, 12, 629-637.	1.2	19
124	Artery Dissection and Arterial Thrombus Aging. Circulation, 2001, 103, 2420-2421.	1.6	19
125	Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. Atherosclerosis, 2009, 202, 185-191.	0.4	19
126	Estimation of the major cardiovascular events prevention with Inclisiran. Atherosclerosis, 2020, 313, 76-80.	0.4	19

#	Article	IF	Citations
127	Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients. Thrombosis and Haemostasis, 2006, 95, 441-446.	1.8	18
128	Incremento de las HDL como arma terapÃ©utica en la aterotrombosis. Revista Espanola De Cardiologia, 2010, 63, 323-333.	0.6	18
129	Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term. Thrombosis and Haemostasis, 2012, 108, 1246-1248.	1.8	18
130	Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation. PLoS ONE, 2017, 12, e0171486.	1.1	16
131	Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet thrombogenicity. Atherosclerosis, 2020, 294, 17-24.	0.4	16
132	Shear stress-dependent platelet function after LDL cholesterol apheresis. Thrombosis Research, 2004, 113, 395-398.	0.8	15
133	Coronary Artery Disease in Aging Women: A Menopause of Endothelial Progenitor Cells?. Medical Clinics of North America, 2012, 96, 93-102.	1.1	15
134	Accelerated Reendothelialization, Increased Neovascularization and Erythrocyte Extravasation after Arterial Injury in BAMBIâ^'/â^' Mice. PLoS ONE, 2013, 8, e58550.	1.1	15
135	HDL Dysfunction. Journal of the American College of Cardiology, 2015, 66, 1486-1488.	1.2	15
136	Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thrombosis and Haemostasis, 2017, 117, 1981-1988.	1.8	15
137	The anti-inflammatory effects of SGLT inhibitors. Aging, 2019, 11, 5866-5867.	1.4	15
138	Clinical and Experimental Experience with Factor Xa Inhibitors. American Journal of Cardiovascular Drugs, 2004, 4, 379-384.	1.0	13
139	Platelet reactivity and nonresponse to dual antiplatelet therapy: A review. Platelets, 2009, 20, 531-538.	1.1	13
140	Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. Thrombosis Research, 2014, 133, 880-885.	0.8	13
141	Susceptibility to chronic social stress increases plaque progression, vulnerability and platelet activation. Thrombosis and Haemostasis, 2017, 117, 816-818.	1.8	13
142	LipoproteÃnas de alta densidad y reducciÃ³n de riesgo cardiovascular: Â¿promesas o realidades?. Revista Espanola De Cardiologia, 2012, 65, 305-308.	0.6	12
143	Incremental effects of diabetes mellitus and chronic kidney disease in medial arterial calcification: Synergistic pathways for peripheral artery disease progression. Vascular Medicine, 2019, 24, 383-394.	0.8	12
144	Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions. Atherosclerosis, 2017, 266, 81-86.	0.4	11

#	Article	IF	Citations
145	Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis. Journal of Immunological Methods, 2018, 453, 11-19.	0.6	11
146	Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection. Cardiovascular Drugs and Therapy, 2021, , 1.	1.3	11
147	Can We Image the â€œActiveâ€•Thrombus?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1753-1754.	1.1	10
148	Validation Study of a Semi-Automated Program for Quantification of Atherosclerotic Burden. Journal of Cardiovascular Magnetic Resonance, 2007, 9, 615-620.	1.6	10
149	Statin Therapy Alone and in Combination with an Acyl-CoA:Cholesterol <i>O</i>-Acyltransferase Inhibitor on Experimental Atherosclerosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 9-17.	0.5	10
150	Safe and Sustained Overexpression of Functional Apolipoprotein A-I/High-density Lipoprotein in Apolipoprotein A-Iâ€“null Mice by Muscular Adeno-associated Viral Serotype 8 Vector Gene Transfer. Journal of Cardiovascular Pharmacology, 2009, 54, 405-411.	0.8	10
151	Modulatory Role of Pulsatility on vonÂWillebrand Factor. Journal of the American College of Cardiology, 2018, 71, 2119-2121.	1.2	10
152	Adeno-associated Virus Serotype 8 ApoA-I Gene Transfer Reduces Progression of Atherosclerosis in ApoE-KO Mice: Comparison of Intramuscular and Intravenous Administration. Journal of Cardiovascular Pharmacology, 2011, 57, 325-333.	0.8	9
153	The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. Clinical Lipidology, 2011, 6, 181-208.	0.4	9
154	High-Density Lipoprotein and Cardiovascular Risk Reduction: Promises and Realities. Revista Espanola De Cardiologia (English Ed), 2012, 65, 305-308.	0.4	9
155	Peroxisome proliferator-activated receptor ligands in atherosclerosis. Expert Opinion on Investigational Drugs, 2004, 13, 1393-1403.	1.9	8
156	Novel Imaging Techniques for Quantifying Overall Atherosclerotic Burden. Revista Espanola De Cardiologia (English Ed), 2007, 60, 299-309.	0.4	8
157	Increasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease. Revista Espanola De Cardiologia (English Ed), 2010, 63, 323-333.	0.4	8
158	Cardiac Complications After Community-Acquired Pneumonia. American Journal of Cardiology, 2016, 117, 310.	0.7	8
159	Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways. Thrombosis and Haemostasis, 2017, 117, 2312-2321.	1.8	8
160	Idarucizumab, but not procoagulant concentrates, fully restores dabigatranâ€altered platelet and fibrin components of hemostasis. Transfusion, 2019, 59, 2436-2445.	0.8	8
161	Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thrombosis and Haemostasis, 2002, 88, 733-8.	1.8	8
162	Measures of Thrombosis and Fibrinolysis. Clinics in Laboratory Medicine, 2006, 26, 655-678.	0.7	7

#	Article	IF	Citations
163	SGLT receptors and myocardial ischaemia-reperfusion injury: inhibition of SGLT-1, SGLT-2, or both?. Cardiovascular Research, 2019, 115, 1572-1573.	1.8	7
164	Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy. Expert Review of Cardiovascular Therapy, 2020, 18, 635-642.	0.6	7
165	Not only how much, but also how to, when measuring epicardial adipose tissue. Magnetic Resonance Imaging, 2022, 86, 149-151.	1.0	7
166	Catheter-based Renal Denervation as a Treatment for Pulmonary Hypertension: Hope or Hype?. Revista Espanola De Cardiologia (English Ed), 2015, 68, 551-553.	0.4	6
167	Duration of antiplatelet therapy after complex PCI in the TWILIGHT-COMPLEX trial: the Goldilocks dilemma. Cardiovascular Research, 2020, 116, e93-e95.	1.8	6
168	Benefits and Risks of Simvastatin in Patients with Familial Hypercholesterolaemia. Drug Safety, 2003, 26, 769-786.	1.4	5
169	DenervaciÃ³n renal por catÃ©ter como tratamiento para la hipertensiÃ³n pulmonar: Â¿esperanza o espejismo?. Revista Espanola De Cardiologia, 2015, 68, 551-553.	0.6	5
170	Niacin is still beneficial. Implications from an updated meta-regression analysis. Acta Cardiologica, 2016, 71, 463-472.	0.3	5
171	Dual antiplatelet therapy and drug eluting stents: a marriage of convenience. Thrombosis Journal, 2007, 5, 15.	0.9	4
172	Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. Thrombosis and Haemostasis, 2014, 112, 1069-1070.	1.8	4
173	High-Density Lipoproteinâ€“Targeted Therapiesâ€”Not Dead Yet. JAMA Cardiology, 2018, 3, 1254.	3.0	4
174	Acute biological response to laser balloon angioplasty in the atherosclerotic rabbit. Lasers in Surgery and Medicine, 1994, 14, 7-12.	1.1	3
175	Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions. Clinical Medicine Cardiology, 2008, 2, CMC.S642.	0.1	3
176	Modelos experimentales de aterosclerosis. Revista Espanola De Cardiologia Suplementos, 2013, 13, 3-12.	0.2	3
177	Spark That Lights the Fire: Infection Triggers Cardiovascular Events. Journal of the American Heart Association, 2018, 7, e011175.	1.6	3
178	Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?. Journal of Cardiovascular Pharmacology, 2020, 75, 269-275.	0.8	3
179	Effects of electret coating technology on coronary stent thrombogenicity. Platelets, 2022, 33, 312-319.	1.1	3
180	Ezetimibe: one step beyond in the battle against atherosclerosis. Future Lipidology, 2006, 1, 255-266.	0.5	2

#	Article	IF	Citations
181	Reply. Journal of the American College of Cardiology, 2019, 74, 826.	1.2	2
182	Is Increased Cardiovascular and Bleeding Risk the Price for Pain Relief?. Journal of the American College of Cardiology, 2020, 76, 530-532.	1.2	2
183	Â¿Son los inhibidores del receptor SGLT2 fÃ¡rmacos antidiabÃ©ticos o cardiovasculares?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 33-40.	0.4	2
184	Dual versus triple antithrombotic therapy: is there a role for direct oral anticoagulants in arterial thrombosis?. Drugs of Today, 2019, 55, 197.	0.7	2
185	Reply. Journal of the American College of Cardiology, 2015, 65, 1490-1491.	1.2	1
186	Role of Niacin in Cardiovascular Prevention: The Debate Continues. American Journal of Medicine, 2017, 130, e345.	0.6	1
187	Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2021, 33, 33-40.	0.1	1
188	Perâ€Protocol Versus Intentionâ€toâ€Treat in Clinical Trials: The Example of GLOBALâ€LEADERS Trial. Journal of the American Heart Association, 2022, 11, e025561.	1.6	1
189	Pathogenesis of Atherosclerosis. , 2006, , 49-85.		0
190	Papel de la proteÃna trasferidora de Ã©steres de colesterol en aterosclerosis: mÃ¡s preguntas que respuestas, mÃ¡s dudas que promesas. Revista Colombiana De Cardiologia, 2012, 19, 180-183.	0.1	0
191	Characteristics of the Metabolic Syndrome in the Patients of IBERICAN Study (Identification of the) Tj ETQq1 1 0.784314 rgBT /Overlock 2017, 15, 431-438.	0.5	0
192	Reply: empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention. Expert Review of Cardiovascular Therapy, 2021, 19, 101-102.	0.6	0
193	Magnetic Resonance Imaging of High- Risk Plaque. , 2004, , 101-128.		0
194	Platelets and the vulnerable plaque. , 2007, , 39-51.		0
195	TF Independent Potentiation of FVIIa Activity in CAD Plasma: An Assessment Using Two Chromogenic Assays.. Blood, 2008, 112, 1820-1820.	0.6	0
196	Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood. , 2011, , 53-66.		0
197	LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Drugs of Today, 2019, 55, 329.	0.7	0
198	HDL: un nuevo biomarcador para la insuficiencia cardiaca. Revista Espanola De Cardiologia (English Ed) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.4	0